B cells express other ITIM-containing membrane molecules such as CD22
, Siglec-G/Siglec-10, PIR-B, and PECAM-1.
The monoclonal antibodies (MoAb) used for diagnosis of AL were: for B-lineage: CD19, CD22
, CD20, CD10, for T-lineage: CD2, CD3, CD5, CD7, CD4, CD8, for myelo-monocytic lineage: CD13, CD33, CD11c, CD64, CD14, other cells surface markers: CD34, CD117, HLA-DR and intracellular MoAb: CD79a, CD3 and MPO.
Flow cytometry was performed using a broad panel of antibodies including CD10, CD19, CD20, CD22
, cCD79a and cCD3 (Figure-1).
Beponsa is an ADC comprised of a monoclonal antibody (mAb) targeting CD22
, a cell surface antigen expressed on cancer cells, linked to a cytotoxic agent.
World Health Organization 2008/2016 Criteria for Mixed-Phenotype Blasts (a) Lineage Markers Myeloid MPO (flow cytometry, immunohistochemistry, or enzyme cytochemistry) -OR- Monocytic differentiation (at least 2 of the following: NSE cytochemistry, CD11c, CD14, CD64, lysozyme) T lineage Strong (b) cytoplasmic CD3 -OR- Surface CD3 B lineage Strong (b) CD19 with at least 1 of the following strongly expressed: CD79a, cytoplasmic CD22
, or CD10 -OR- Weak CD19 with at least 2 of the following strongly expressed: CD79a, cytoplasmic CD22
, or CD10 Abbreviations: MPO, myeloperoxidase, NSE, nonspecific esterase.
1 By binding to B cell-specific CD22
receptors, BESPONSA is internalized, triggering the release of the cytotoxic agent that causes double-strand DNA breaks and apoptosis.
The product is a targeted therapy, which is believed to work by binding to B-cell ALL cancer cells that express the CD22
antigen, thereby blocking the growth of cancerous cells.
A population of clonal B cells was identified that expressed CD5, CD19, CD20 (dim), CD22
, CD23, CD45, and HLA-DR, and were kappa light chain restricted.
2008 WHO Diagnostic Criteria for MPAL  Lineage Markers Myeloid Myeloperoxidase or Monocytic differentiation (At least two of the following: NSE, CD11c, CD14, CD64, lysozyme) T Lineage Cytoplasmic CD3 or Surface CD3 B Lineage Strong CD19 and at least one of the following with strong expression: CD79a, cytoplasmic CD22
or CD10 OR Weak CD19 and at least two of the following with strong expression: CD79a, cytoplasmic CD22
or CD10 Table 2.
is a clinically validated ADC target with potential in non-Hodgkin's lymphoma (NHL) and acute lymphoid leukemia (ALL).
Inotuzumab ozogamicin, also known as CMC-544, links an antibody that targets CD22
, a protein found on the surface of more than 90 percent of ALL cells.
The gene analysis of signaling molecules specific for B lymphocytes identified two inhibitor receptors, Lyn and CD22
, which are critical in the regulation of B lymphocyte phenotype expressed in SLE.